A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
NCT06901349 | Bimagrumab | Phase 2 | Withdrawn | Eli Lilly and Company | – | Jun 10, 2025 | Sep 24, 2025 |
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
NCT05896384 | Survodutide | Phase 1 | Completed | Boehringer Ingelheim | 32 | Feb 14, 2025 | Apr 16, 2025 |
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
NCT04771273 | Survodutide | Phase 2 | Completed | Boehringer Ingelheim | 295 | Nov 9, 2023 | Dec 3, 2024 |
A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain
NCT05298306 | AOD-9604 | Phase 1 | Completed | Lateral Pharma Pty Ltd | 26 | May 12, 2023 | Nov 27, 2024 |
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
NCT05296733 | Survodutide | Phase 1 | Completed | Boehringer Ingelheim | 82 | Dec 29, 2023 | Aug 15, 2024 |
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
NCT03856047 | Cagrilintide | Phase 2 | Completed | Novo Nordisk A/S | 706 | Mar 2, 2020 | Jul 5, 2024 |
AT1001 for the Treatment of COVID-19 Related MIS-C
NCT05022303 | Larazotide | Phase 2 | Terminated | Massachusetts General Hospital | 12 | May 15, 2024 | Jun 13, 2024 |
A Study of LY3841136 in Healthy and Overweight Participants
NCT05295940 | Eloralintide | Phase 1 | Completed | Eli Lilly and Company | 148 | Jan 25, 2024 | Apr 1, 2024 |
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
NCT04667377 | Survodutide | Phase 2 | Completed | Boehringer Ingelheim | 387 | Sep 15, 2022 | Nov 2, 2023 |
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy
NCT02354781 | Follistatin 344 | Phase 1 / Phase 2 | Completed | Jerry R. Mendell | 3 | Nov 2017 | Oct 11, 2023 |
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
NCT01519349 | Follistatin 344 | Phase 1 | Completed | Nationwide Children's Hospital | 15 | Oct 2017 | Oct 2, 2023 |
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
NCT04881760 | Retatrutide | Phase 2 | Completed | Eli Lilly and Company | 338 | May 16, 2022 | Sep 13, 2023 |
A Study of LY3457263 in Obese Participants
NCT05582096 | Nisotirostide | Phase 1 | Completed | Eli Lilly and Company | 38 | Jun 8, 2023 | Jul 18, 2023 |
A Study of LY3437943 in Participants With Type 2 Diabetes
NCT04867785 | Retatrutide | Phase 2 | Completed | Eli Lilly and Company | 281 | Jul 8, 2022 | Jul 3, 2023 |
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
NCT04153929 | Survodutide | Phase 2 | Completed | Boehringer Ingelheim | 413 | Oct 8, 2021 | Nov 29, 2022 |
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
NCT03569007 | Larazotide | Phase 3 | Terminated | 9 Meters Biopharma, Inc. | 307 | Jul 21, 2022 | Jul 26, 2022 |
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
NCT03600480 | Cagri-Sema, Cagrilintide | Phase 1 | Completed | Novo Nordisk A/S | 96 | Jun 12, 2020 | Nov 17, 2021 |
Oral LAT8881 in Neuropathic Pain
NCT03865953 | AOD-9604 | Phase 2 | Completed | Lateral Pharma Pty Ltd | 53 | Apr 19, 2020 | Jun 14, 2021 |
A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
NCT04153409 | AOD-9604 | Phase 2 | Completed | Lateral Pharma Pty Ltd | 21 | Feb 15, 2020 | Apr 28, 2021 |
A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers
NCT04555824 | TB-500 | Phase 1 | Completed | Beijing Northland Biotech. Co., Ltd. | 54 | Feb 20, 2018 | Sep 29, 2020 |
A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers
NCT04555850 | TB-500 | Phase 1 | Completed | Beijing Northland Biotech. Co., Ltd. | 30 | Feb 18, 2019 | Sep 29, 2020 |
Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147
NCT03838185 | J-147 | Phase 1 | Completed | Abrexa Pharmaceuticals, Inc. | 64 | Feb 1, 2020 | Sep 3, 2020 |
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity
NCT01262664 | Adipotide | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | Jan 2, 2019 | Jan 4, 2019 |
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
NCT01396213 | Larazotide | Phase 2 | Completed | 9 Meters Biopharma, Inc. | 342 | Aug 20, 2013 | Sep 20, 2017 |
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease
NCT00889473 | Larazotide | Phase 2 | Completed | 9 Meters Biopharma, Inc. | 42 | Nov 2009 | Sep 20, 2017 |
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
NCT01925209 | Bimagrumab | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 251 | Jan 6, 2016 | Aug 11, 2017 |
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
NCT02039687 | ARA-290 | Phase 2 | Completed | Araim Pharmaceuticals, Inc. | 64 | Jan 2015 | Apr 18, 2017 |
Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus
NCT00672074 | Ipamorelin | Phase 2 | Completed | Helsinn Therapeutics (U.S.), Inc | 117 | Dec 2009 | Apr 14, 2017 |
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
NCT01280344 | Ipamorelin | Phase 2 | Completed | Helsinn Therapeutics (U.S.), Inc | 320 | Jun 2013 | Apr 13, 2017 |
TH9507 in Patients With HIV-Associated Lipodystrophy
NCT00435136 | Tesamorelin | Phase 3 | Completed | Theratechnologies | 412 | Nov 2006 | Nov 27, 2013 |
TH9507 in Patients With HIV-Associated Lipodystrophy
NCT00123253 | Tesamorelin | Phase 3 | Completed | Theratechnologies | 412 | Nov 2006 | Nov 27, 2013 |
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer’s Type
NCT00153010 | Tesofensine | Phase 2 | Completed | Boehringer Ingelheim | 430 | Mar 2005 | Oct 29, 2013 |
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations
NCT00148512 | Tesofensine | Phase 2 | Completed | Boehringer Ingelheim | 254 | Feb 2005 | Oct 29, 2013 |
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson’s Disease Patients (Study for Proof of Concept in Early Parkinson’s Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
NCT00148486 | Tesofensine | Phase 2 | Completed | Boehringer Ingelheim | 261 | Mar 2005 | Oct 29, 2013 |
Effect of Tesofensine on Weight Reduction in Patients With Obesity.
NCT00394667 | Tesofensine | Phase 2 | Completed | NeuroSearch A/S | 200 | Not stated | Apr 22, 2013 |
Evaluation of Long Term Safety of Tesofensine in Patients With Obesity
NCT00481104 | Tesofensine | Phase 2 | Completed | NeuroSearch A/S | 140 | Sep 2008 | Jul 4, 2011 |
Effect of Tesofensine on Energy Balance in Humans.
NCT00428415 | Tesofensine | Phase 1 / Phase 2 | Completed | NeuroSearch A/S | 32 | Dec 2007 | Mar 5, 2008 |
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity
NCT00267527 | CJC-1295 with DAC | Phase 2 | Terminated | ConjuChem | 120 | Not stated | Oct 16, 2006 |
